The recommendation has not come easy for Roche. Back in October 2014, NICE had rejected Gazyravo based on inconsistencies in the filing, which were then addressed by the drug manufacturer. Subsequently, NICE struck a deal with Roche to provide the drug to NHS at a reduced price.
Patients in England and Wales with chronic lymphocytic leukaemia are a step closer to getting access to Roche’s Gazyvaro (obinutuzumab) on the National Health Service, after cost regulators recommended the drug for routine use.
Gazyvaro is the first ‘type II’ anti-CD20 monoclonal antibody licensed for the treatment of CLL and is designed to attack blood cancers more aggressively than ‘type I’ treatments such as MabThera (rituximab).
Link to the complete article on PharmaTimes: http://bit.ly/1AfH0NA
Lymphoma Research Foundation CEO on Biden’s Cancer Moonshot, Financial Toxicity
February 3rd 2022On this episode of Managed Care Cast, we speak with Meghan Gutierrez, CEO of the Lymphoma Research Foundation, about financial toxicity, how the pandemic has affected patients’ financial needs when they have cancer, health care disparities and care gaps, and more.
Listen
NCCN Launches Pilot Project Aiming to Measure, Implement Health Equity in Cancer Care Practices
February 4th 2023Five leading academic cancer centers are assessing the feasibility of implementing the Health Equity Report Card pilot project as a tool that can both meaningfully and feasibly measure and report on equitable care practices.
Read More
Keeping Patients With Cancer Out of the ED Through Dedicated Urgent Care
October 13th 2021On this episode of Managed Care Cast, we bring you an interview conducted by the editorial director of OncLive® who talks with the advance practice provider chief at Winship Cancer Institute about how having a dedicated cancer urgent care center will make cancer treatment plans seamless whil helping patients avoid exposure to infectious diseases in emergency department waiting rooms.
Listen
Racial and Ethnic Disparities Persist in B-Cell ALL Survival in Children, Young Adults
February 3rd 2023Despite overall improvements in survival outcomes in recent decades, disparities in survival outcomes persist among children and young adults with acute lymphocytic leukemia (ALL) across racial and ethnic groups.
Read More
Study Suggests MRI Is the Best Breast Cancer Screening Modality for Dense Breasts
February 1st 2023A review and meta-analysis published in the journal Radiology found MRI to be the most effective supplemental breast cancer screening method for women with dense breasts and negative mammogram results.
Read More
2 Clarke Drive
Cranbury, NJ 08512